Head to Head Comparison: SciSparc (NASDAQ:SPRC) and TherapeuticsMD (NASDAQ:TXMD)

SciSparc (NASDAQ:SPRC) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, analyst recommendations, risk, dividends and valuation.

Profitability

This table compares SciSparc and TherapeuticsMD’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SciSparc	N/A	N/A	N/A
TherapeuticsMD	5.34%	0.32%	0.23%

Valuation & Earnings

This table compares SciSparc and TherapeuticsMD”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SciSparc	$860,000.00	3.72	-$12.18 million	N/A	N/A
TherapeuticsMD	$3.02 million	8.58	-$570,000.00	$0.06	37.33

TherapeuticsMD has higher revenue and earnings than SciSparc.

Volatility & Risk

SciSparc has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500. Comparatively, TherapeuticsMD has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for SciSparc and TherapeuticsMD, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SciSparc	1	0	0	0	1.00
TherapeuticsMD	1	0	0	0	1.00

Insider and Institutional Ownership

25.1% of SciSparc shares are owned by institutional investors. Comparatively, 30.7% of TherapeuticsMD shares are owned by institutional investors. 1.5% of SciSparc shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

TherapeuticsMD beats SciSparc on 8 of the 9 factors compared between the two stocks.

About SciSparc

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

About TherapeuticsMD

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.